Vaccines currently available to the global market are Bavarian Nordic’s MVA-BN (JYNNEOS), KM Biologics’ LC16, and Emergent ...

The modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine is approved in several countries for the prevention of mpox and smallpox in adults, but insufficient data are available to support ...

One dose of the modified vaccinia Ankara-Bavarian Nordic (MVA-BN; Jynneos) mpox vaccine was moderately effective in preventing mpox infections, according to a Canadian observational, emulated ...

Today's health news includes what RFK Jr. can do on vaccines, escaped monkeys, and who know in the Make America Healthy Again ...

The World Health Organisation and the Africa Centre for Disease Control and Prevention experts have decided to provide ...

Results from this study could support an extension of the current approval of MVA-BN to include children from 2 years of age ...

Receiving a single dose of one type of smallpox vaccine seems to lower the risk of catching mpox by around 60 per cent, ...

There are two vaccines approved against mpox, MVA-BN and LC16. These jabs are based on weakened versions of orthopoxviral and ...

Nineteen African states—those currently reporting or that have reported Mpox cases within this outbreak—gathered in a ‘back-to-school’ style meeting in Congo Brazzaville in the first week of November.

Regardless of 1 or 2 doses, mpox antibodies wane by 6 to 12 months. HealthDay News — Immunity against mpox may be waning for those vaccinated with the modified vaccinia Ankara-Bavarian Nordic ...

The modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine is approved in several countries for the prevention of mpox and smallpox in adults, but insufficient data are available to support ...

Clinical study in children 2-11 years of age follows the recent EMA and WHO approvals of the MVA-BN mpox vaccine for adolescents 12-17 of age. COPENHAGEN, Denmark, October 29, 2024 – Bavarian ...